Cash-Rich Ipsen Opens Up Checkbook For 2019

 
• By Jo Shorthouse

2019 looks set to be a transformative year for Ipsen, with a pivotal clinical trial readout expected for combination Cabometyx in frontline kidney and liver cancer, and a series of deals promised by the company to investors looking for reassurance over long-term growth. CEO David Meek spoke to Scrip.

Cheque
Everything is on the table, and we can act fast, says Ipsen CEO • Source: Shutterstock

More from Strategy

More from Business